Cambridge Enterprise Venture Partners 2023 – Investor Showcase
Wednesday 22 March 2023, 1.00pm-5.00pm
McGrath Centre, St Catharine’s College
Welcome to Cambridge Enterprise Venture Partners (CEVP) and our first Investor Showcase for 2023.
We are delighted that you have been able to join us at St Catharine’s College. Today, you’ll hear six exciting pitches from our portfolio companies who are all in various stages of their journeys and looking for investment. And it is our great pleasure to have Andrew Williamson from Cambridge Innovation Capital as our guest speaker.
We hope you’ll stay with us for a drink afterwards to continue the conversations and networking.
Programme
13:00 – Registration & Lunch
14:00 – Welcome
Dr Christine MartinHead of Seed Funds, Cambridge Enterprise
As Head of Seed Funds, Christine overseeas our investment activities, with the team investing over £5 million each year in young compaines.
With expertise in Life Science investment, Christine has a focus on drug discovery with a broad portfolio of technologies, including University of Cambridge spin-outs Carrick, STORM, Z-factor, PhoreMost, Qkine, and PolyProX. Christine was featured in BioBeat’s 50 Movers and Shakers in BioBusiness 2018.
Christine joined Cambridge Enterprise in September 2011.
14:10 – Showcase Pitches, Session 1
Presenting Companies:
PredictImmune
Helping patients diagnosed with chronic immune-mediated disorders to live normal and healthy lives.
PredictImmune developes prognostic assays that predict disease progression for patients with immune-mediated disorders. Our flagship product is PredictSURE® IBD, a novel blood test that identifies a patient’s risk of developing severe relapsing-remitting Crohn’s disease or ulcerative colitis, the two most common forms of inflammatory bowel disease (IBD), early in the course of their disease.
Our technology is based on over 15 years’ research at the University of Cambridge. PredictSURE®IBD can guide personalised treatment to deliver the best health outcome for each individual. We are headquartered in Cambridge, UK, with supply and distribution partnerships in the UK, EU and USA.
Funding Opportunity
PreditImmune are raising £7m equity financing to commercialise PredictSURE® IBD, and
– Build out team in US and UK
– Secure regulatory approval in US and selected markets
– Drive adoption and reimbursement
– Industrialise and scale operations
Find out more
Matta
Building AI to Manufacture the Impossible
At Matta we are building the AI operating system for additive manufacturing. Our technology is based on state-of-the-art research by engineers and scientists at Cambridge. We have developed the first AI platform that can detect almost all errors autonomously and then correct them on the fly.
This will enable the creation of highly complex products with unrivalled consistency, unlocking new capabilities in sectors like robotics, spaceflight, and bespoke medical devices.
Funding Opportunity
Seeking Pre-seed funding of £750k+
Find out more
Biophonics
Enabling widespread early detection of valvular heart disease with a unique medical device
Nearly 2 million people in the UK suffer from significant valvular heart disease, yet more than half remain undiagnosed.
Biophonics are a spin-out from the Acoustics Lab in Cambridge University Engineering Department, combining world-leading AI and acoustics to design a unique screening device for valvular heart disease. Our device will enable community screening to be carried out by a non-skilled operator, detecting cases at an early stage and preventing costly late intervention due to heart failure
Funding Opportunity
Seeking Seed funding of £1.9m
Find out more
14:40 – Coffee Break
15:15 – Showcase Pitches, Session 2
Presenting Companies:
OutSee
Discovering novel drug targets using an innovative AI genomics technology that uncovers disease-modulating biological mechanisms.
OutSee is being launched to take advantage of the opportunity to exploit large-scale genomics datasets by using its proprietary AI genomics technology for novel drug target discovery and validation. The technology, recently published in Nature Comms, has been 10 years in development in academia.
Funding Opportunity
OutSee is seeking to raise a £2.3M Seed round to initiate internal programmes and build pharma partnerships over 2 years.
Find out more
Sparxell
The next generation of colours and effects
Glitters can take many sizes and shapes (from the sequins used in fashion to the fine powder used in the paint of 1 in 4 cars sold in Europe or found in cosmetics) yet they all contain problematic microplastics, metals, or mineral oxides. Science warns us that these products accumulate and enter our water supply.
Sparxell has created safer and easier-to-source alternative pigments with vibrant colour and benefits that appeal to health and eco-conscious consumers and companies alike.
Funding Opportunity
Sparxell is seeking to raise a $2.0M Seed round to
1. commence hiring,
2. deliver larger quantities of products with fine-tuned properties to interested partners, and
3. rent larger production equipment.
Find out more
WavePhotonics
A platform to unleash the potential of integrated photonics
Integrated photonics uses the same process used to make conventional semiconductor chips to make circuits for light. This makes it possible to take many light-based technologies from the lab and make them useful to humanity via the scalability of semiconductor processing.
Wave Photonics is building a platform based on its core computational design technology which will enable designers to take products from idea to volume using pre-designed, adaptable components and integrations with packagers and other service providers
Funding Opportunity
With the Pre-seed funding round of £170k, Wave have built and proven the core technology.
Wave are now seeking to raise £2.5m in Seed funding to build this into a product suitable for volume production.
Find out more
15:45 – Guest speaker
Andrew WilliamsonManaging Partner, Cambridge Innovation Capital
Andrew’s background combines R&D, start-up formation and technology investing. Before joining CIC he spent ten years in venture investing at Physic Ventures in San Francisco and True North Venture Partners in Chicago. Before moving into Venture Capital, Andrew led a research group applying High Performance Computing to materials science at Lawrence Livermore National Laboratory.
Andrew has an MA and PhD in Physics from the University of Cambridge and an MBA from the Haas School of Business at the University of California, Berkeley.
Andrew focuses on technology investments and manages CIC’s investments in Pragmatic, NStream (formerly SWIM) and Riverlane.